Fig. 2.

Upper row: Vaccine-associated hypermetabolic lymphadenopathy rates in serology-based groups. Note the low rates of VAHL in patients with negative serology result. Lower row: Note the significant higher positive serology rate in patients with VAHL on imaging. All-PET group refers to all patients with hematologic malignancy that underwent [¹⁸F]FDG PET-CT after BNT162b2 administration. PET-2 group includes those received the first and booster vaccine doses before imaging. ^a: a statistically significant difference of no VAHL rates was found between negative serology and low titer groups; ^b: a statistically significant difference of no VAHL rates was found between negative serology and high titer groups; ^c: a statistically significant difference of no VAHL rates was found between low titer and high titer groups; ^d: a statistically significant difference of grade 1–2 VAHL rates was found between negative serology and high titer groups; ^e: a statistically significant difference of grade 1–2 VAHL rates was found between low titer and high titer groups